Active Surveillance:
Monitoring Prostate Cancer with Confidence

Active surveillance (AS) is a structured plan for men with low-risk prostate cancer that prioritizes regular monitoring over immediate treatment. The goal is to preserve quality of life while staying safe, with curative treatment available if test results show signs of progression.

What Active Surveillance Is (and Isn’t)

Active surveillance is not doing nothing. Typical elements include:

  • PSA blood tests about every 6 months
  • Digital rectal exam (DRE) about once a year
  • Prostate MRI to refine risk and guide biopsies
  • Periodic prostate biopsies (often every 1–3 years)

Monitoring schedules are personalized based on risk, age, health, and preferences.

PSA Density

PSA density (PSAD) adjusts the PSA number by factoring in prostate size. A larger prostate naturally produces more PSA, which can make the PSA level appear higher even without cancer. By dividing the PSA level by the volume of the prostate (measured on MRI or ultrasound), doctors can get a clearer picture of cancer risk. PSA density can help reduce unnecessary biopsies, but it is not a standalone test — it should be considered alongside PSA levels, imaging, and other clinical findings.

Prostate MRI (Multiparametric MRI, or mpMRI)

A prostate MRI takes detailed pictures of the prostate using different imaging sequences. It can show areas that look suspicious for cancer, estimate the size of the prostate, and help guide whether a biopsy is needed or where to target it. An MRI can make monitoring on Active Surveillance safer by spotting changes over time. It does not replace a biopsy, but it can help reduce unnecessary biopsies and give doctors more confidence about what’s happening inside the prostate.

PI-RADS (Prostate Imaging Reporting & Data System)

PI-RADS is a standardized system radiologists use to interpret prostate MRIs. It communicates how suspicious a particular area looks for clinically significant prostate cancer:

  • PI-RADS 1 — Highly unlikely to be cancer
  • PI-RADS 2 — Unlikely
  • PI-RADS 3 — Equivocal or uncertain
  • PI-RADS 4 — Likely
  • PI-RADS 5 — Highly likely

Doctors use PI-RADS scores to help decide whether a biopsy should be done — and if so, where to target it.

Who Commonly Chooses Active Surveillance

Early prostate cancer often causes no symptoms. As it progresses, symptoms may include:

  • Low-risk disease (often Grade Group 1 / Gleason 6), PSA < 10, clinical stage T1–T2a
  • Cancer confined to the prostate, low tumor volume on biopsy and consistent imaging

Benefits and Considerations

Potential Benefits:

  • Delay or avoid treatment side effects (urinary, sexual, bowel)
  • Maintain quality of life under a structured plan
  • Option to shift to curative treatment if cancer changes

Considerations:

  • Requires ongoing tests and follow-up
  • Some men may feel anxious about monitoring
  • A small percentage may harbor higher-grade cancer found later, which is why surveillance includes biopsies

What Experts Emphasize

  • Active surveillance is preferred for many men with low-risk disease and has low rates of metastasis and prostate cancer–specific death at 10 years in large cohorts.
  • MRI augments risk stratification but does not replace periodic biopsy.
  • PSA is commonly checked every 6 months, with DRE every 1–2 years; frequency is individualized.

Trusted Resources & Further Reading

*Disclaimer: The information on this page is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider, such as a physician or urologist, about your personal care. Ask questions, seek multiple opinions if needed, and make decisions in partnership with your medical team.